<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948986</url>
  </required_header>
  <id_info>
    <org_study_id>8835-009</org_study_id>
    <secondary_id>B1521023</secondary_id>
    <nct_id>NCT01948986</nct_id>
  </id_info>
  <brief_title>Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)</brief_title>
  <official_title>A Phase 1, Non-Randomized, Open-Label, Single Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effect of renal impairment on the pharmacokinetics,
      pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2
      diabetes mellitus (T2DM) and in healthy participants with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Up to 96 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion Over 24 Hours (UGE0-24hr)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>T2DM with No Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM and with no renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM with Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM and with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM with Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM and with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM with Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM and with severe (not on dialysis) renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants with No Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants with no renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Single oral administration of tablets.</description>
    <arm_group_label>T2DM with No Renal Impairment</arm_group_label>
    <arm_group_label>T2DM with Mild Renal Impairment</arm_group_label>
    <arm_group_label>T2DM with Moderate Renal Impairment</arm_group_label>
    <arm_group_label>T2DM with Severe Renal Impairment</arm_group_label>
    <arm_group_label>Healthy Participants with No Renal Impairment</arm_group_label>
    <other_name>MK-8835</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of approximately 18 to 40 kg/m^2

          -  Stable renal function

          -  Male or female not of reproductive potential

          -  Female of reproductive potential must agree or have their partner agree to use 2
             acceptable methods of contraception

          -  Healthy subjects determined to be healthy by investigator screening

          -  T2DM participants have a diagnosis of T2DM as per American Diabetes Association
             guidelines

          -  T2DM participants to be on a stable anti-hyperglycemic regimen with no new drug or
             drug dosage within 8 weeks of study participation. Variations in daily dose of insulin
             up to 10% are permitted.

        Exclusion Criteria:

          -  A positive urine drug screen for drugs of abuse or recreational drugs

          -  Pregnant or nursing females

          -  History of abuse of alcohol or illicit drugs

          -  Significant renal or urinary disease within 6 months of study participation

          -  History of malignancy within the past 5 years basal cell carcinoma of the skin or
             cervical cancer in situ

          -  History of human immunodeficiency virus (HIV)

          -  History of blood dyscrasias or any disorders causing hemolysis or unstable red blood
             cells

          -  Any acute disease state (eg, , vomiting, fever, diarrhea) within 7 days before study
             participation

          -  Treatment with an investigational drug within 30 days of study participation

          -  Use of herbal supplements within 28 days prior to study participation

          -  Any clinically significant malabsorption condition

          -  Blood donation (excluding plasma donations) of approximately 1 pint within 56 days
             prior to study participation

          -  History of sensitivity to ertugliflozin or other Sodium-Glucose co-Transporter 2
             (SGLT2) inhibitors

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia

          -  Unwilling or unable to comply with the study Lifestyle Guidelines

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease including clinically relevant and significant drug allergies

          -  Use of prescription drugs (hormonal methods of birth control are allowed), vitamins
             and dietary supplements within 7 days of study participation

          -  For T2DM participants, history of type 1 diabetes mellitus or a history of
             ketoacidosis

          -  For T2DM participants, clinically significant electrocardiogram abnormality

          -  For T2DM participants, history of myocardial infarction, unstable angina, coronary
             revascularization, stroke or transient ischemic attack within 3 months of study
             participation

          -  For T2DM participants, heart failure defined as New York Heart Association Functional
             Class III-IV

          -  For T2DM participants, renal allograft recipients

          -  For T2DM participants, requiring dialysis

          -  For T2DM participants, strict fluid restriction

          -  For T2DM participants, urinary incontinence

          -  For T2DM participants, acute renal disease

          -  For T2DM participants, significant hepatic, cardiac, or pulmonary disease or
             clinically nephrotic

          -  For T2DM participants, prescription and over-the-counter medication that is not taken
             according to a stable regimen for 7 days before study participation

          -  For T2DM participants, on metformin should not be enrolled if their baseline renal
             function is outside the approved product labeling

          -  For T2DM participants receiving any of the following medications within 7 days of
             study participation: 1. Other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin,
             empagliflozin); 2. Other injectable anti-hyperglycemic agents including pramlintide or
             Glucagon-like peptide-1 (GLP-1) analogues; 3. Any immunosuppressive drugs, including
             cyclosporine, tacrolimus, sirolimus; 4. Oral corticosteroids (note that inhaled, nasal
             and topical corticosteroids are permitted); 5. Any potent drug-metabolizing
             enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; 6. Probenecid,
             valproic acid, gemfibrozil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 3, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 25, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

